With Solid Growth And Strong Pipeline, Argus Is Positive On Celgene's Long-Term Prospects

0 Comments 4 view(s)

In a report issued Tuesday, Argus analyst David Toung shared a look into Focus List-selected Celgene Corporation (NASDAQ: CELG), reiterating a Buy rating and $155 price target.

Latest Ratings for CELG

Date Firm Action From To
Aug 2016 BTIG Research Upgrades Neutral Buy
Jul 2016 Stifel Initiates Coverage on Buy
Jun 2016 BTIG Research Downgrades Buy Neutral

View More Analyst Ratings for CELG

View the Latest Analyst Ratings